Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Technology in Parkinson's disease: Challenges and opportunities.

Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, Dorsey ER, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S; Movement Disorders Society Task Force on Technology.

Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26642. [Epub ahead of print] Review.

PMID:
27125836
2.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Mar 28. [Epub ahead of print]

PMID:
27021906
3.

Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease.

Nowinski CJ, Siderowf A, Simuni T, Wortman C, Moy C, Cella D.

Mov Disord. 2016 Feb 26. doi: 10.1002/mds.26546. [Epub ahead of print] Review.

PMID:
26919664
4.

Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.

Kianirad Y, Simuni T.

Curr Neurol Neurosci Rep. 2016 Apr;16(4):34. doi: 10.1007/s11910-016-0635-8.

PMID:
26898686
5.

Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson's Disease patients assessed using pseudo-continuous arterial spin labeling.

Chen Y, Pressman P, Simuni T, Parrish TB, Gitelman DR.

PeerJ. 2015 Nov 3;3:e1381. doi: 10.7717/peerj.1381. eCollection 2015.

6.

Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review.

Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM.

J Parkinsons Dis. 2015;5(4):993. doi: 10.3233/JPD-159002. No abstract available.

PMID:
26683786
7.

Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.

Bega D, Kim S, Zhang Y, Elm J, Schneider J, Hauser R, Fraser A, Simuni T.

J Parkinsons Dis. 2015;5(4):773-82. doi: 10.3233/JPD-150668.

PMID:
26639661
8.

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

Simon DK, Simuni T, Elm J, Clark-Matott J, Graebner AK, Baker L, Dunlop SR, Emborg M, Kamp C, Morgan JC, Ross GW, Sharma S, Ravina B; NINDS NET-PD Investigators.

J Parkinsons Dis. 2015;5(4):731-6. doi: 10.3233/JPD-150666.

PMID:
26444095
9.

Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review.

Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM.

J Parkinsons Dis. 2015;5(3):621. doi: 10.3233/JPD-159001. No abstract available.

PMID:
26406143
10.

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators.

Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10.

PMID:
26271532
11.

Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.

Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, Mendick S, Seibyl J, Simuni T, Zhang Y, Jankovic J, Hunter C, Tanner CM, Rees L, Factor S, Berg D, Wurster I, Gauss K, Sprenger F, Seppi K, Poewe W, Mollenhauer B, Knake S, Mari Z, McCoy A, Ranola M, Marek K.

Mov Disord. 2015 Dec;30(14):1885-92. doi: 10.1002/mds.26325. Epub 2015 Aug 11.

PMID:
26260437
12.

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators.

Lancet Neurol. 2015 Aug;14(8):795-803. doi: 10.1016/S1474-4422(15)00144-1. Epub 2015 Jun 23. Erratum in: Lancet Neurol. 2015 Oct; 14(10):979.

13.

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.

Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, Mayer G, Högl B, Postuma R, Videnovic A, Amara AW, Marek K; PPMI Sleep Working group on behalf of the PPMI Investigators.

Mov Disord. 2015 Sep;30(10):1371-81. doi: 10.1002/mds.26248. Epub 2015 Jun 11.

PMID:
26095202
14.

Motor cortical oscillations are abnormally suppressed during repetitive movement in patients with Parkinson's disease.

Stegemöller EL, Allen DP, Simuni T, MacKinnon CD.

Clin Neurophysiol. 2016 Jan;127(1):664-74. doi: 10.1016/j.clinph.2015.05.014. Epub 2015 May 29.

PMID:
26089232
15.

How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease?

Stegemöller EL, Schmidt P, Hass C, Malaty I, Okun MS; National Parkinson Foundation Quality Improvement Initiative Investigators.

Arch Phys Med Rehabil. 2015 Sep;96(9):1728-32. doi: 10.1016/j.apmr.2015.03.021. Epub 2015 Apr 14.

PMID:
25883039
16.

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; Parkinson's Progression Markers Initiative.

Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4.

PMID:
25737166
17.

The Profile of Long-term Parkinson's Disease Survivors with 20 Years of Disease Duration and Beyond.

Hassan A, Wu SS, Schmidt P, Simuni T, Giladi N, Miyasaki JM, Bloem BR, Malaty IA, Okun MS.

J Parkinsons Dis. 2015;5(2):313-9. doi: 10.3233/JPD-140515.

PMID:
25720446
18.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM.

JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.

19.

Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice?

Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T.

Neurodegener Dis. 2015;15(2):81-6. doi: 10.1159/000370116. Epub 2015 Jan 15.

PMID:
25592727
20.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.

Smith KM, Eyal E, Weintraub D; ADAGIO Investigators.

JAMA Neurol. 2015 Jan;72(1):88-95. doi: 10.1001/jamaneurol.2014.2472.

PMID:
25420207
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk